Lucentis 10 mg/ml solution for injection

DRUG3 trials

Sponsors

Curateq Biologics Private Limited, Curateq Biologics Private Limited, Eyebiotech Limited, Eyebiotech Limited, Eyebiotech Limited

Conditions

Diabetic Macular Edemawet macula degeneration

Phase 2

A RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, 3-ARM PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL EYE103 COMPARED WITH INTRAVITREAL RANIBIZUMAB (0.5MG) IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA

Active, not recruitingCTIS2024-510944-30-00

Eyebiotech Limited, Eyebiotech LimitedDiabetic Macular Edema

Start: 2024-11-22Target: 585Updated: 2026-01-19

A Randomized, Double-masked, Multi-center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema

Active, not recruitingCTIS2025-520809-12-00

Eyebiotech LimitedDiabetic Macular Edema

Start: 2025-10-16Target: 465Updated: 2025-11-19

Phase 3

A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration

CompletedCTIS2023-507459-31-03

Curateq Biologics Private Limited, Curateq Biologics Private Limitedwet macula degeneration

Start: 2024-05-22End: 2025-10-14Target: 70Updated: 2025-05-16